Myqorzo (aficamten) is a prescription oral therapy indicated for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults to improve functional capacity and reduce symptoms.

It is a cardiac myosin inhibitor that binds to the motor protein myosin in the heart muscle, reducing excessive contractile force and decreasing left ventricular outflow tract obstruction that characterizes oHCM. By controlling hypercontractility, Myqorzo helps improve exercise tolerance and symptom burden in affected patients.

Myqorzo is taken as a once-daily tablet with dosing individualized based on clinical response and safety monitoring. Due to the potential for reduced ejection fraction and risk of heart failure, treatment requires regular cardiac monitoring and is available through a Risk Evaluation and Mitigation Strategy (REMS) program.